Media release

Canexis Pharma receives extended GMP manufacturing authorization from Swissmedic – further expansion to become a full-service provider of pharmaceutical cannabis products

Schlattingen, July 14, 2025 – Canexis Pharma ("Canexis"), an innovation-driven Swiss company specializing in pharmaceutical cannabis products, has received manufacturing authorization from Swissmedic, the Swiss Agency for Therapeutic Products, to manufacture finished medicinal products. This means that Canexis is now officially authorized to manufacture bulk finished medicinal products for the production of prescription drugs in large containers, in addition to active pharmaceutical ingredients. Canexis already obtained the necessary authorization for the manufacture of active pharmaceutical ingredients in spring 2024, and as a result, the first long-term active pharmaceutical ingredient supply agreements with partners in drug development were concluded in the first half of 2025.

The extended approval from Swissmedic and the resulting expansion of production expertise for bulk pharmaceuticals testify to the high level of production, process, and quality at Canexis and mark a strategically important step toward the vertical integration of the company. Canexis can now cover an even larger part of the pharmaceutical value chain – from the manufacture of high-purity active ingredients such as dronabinol (THC) to the supply of bulk drugs for pharmacies and clinical trials in the international prescription drug market. Bulk drugs are not yet intended for end consumers and must be further processed, e.g., by repackaging into smaller units, packaging, or labeling. With the award of EU GMP Part I, Canexis is positioning itself globally as a reliable B2B partner for pharmaceutical companies and pharmacies.

In addition, Canexis recently succeeded in producing standardized extracts in development batches with an active ingredient content that is more than 20% higher than the market standard. This quality advantage enables the highly efficient production of naturally derived dronabinol—a first in the field of plant-based cannabinoids in the pharmaceutical sector.

Up to 100 kilograms of pure active ingredient per day from our own production

By the end of 2025, Canexis will be able to offer both active ingredients and GMP-compliant bulk drugs as a full-service provider of pharmaceutical cannabis products. This underscores the company's ambition to become the innovation and quality leader in the pharmaceutical cannabis sector. International exports to markets such as Europe, Latin America, Asia, Oceania, and Africa are already in preparation. At the same time, the rapidly growing Swiss pharmacy market for pharmaceutical cannabis products will also be supplied with standardized formulations and bulk drugs from the company's own GMP production by the end of the year. This will improve the availability of cannabis products on prescription for patients in Switzerland.

The company's own modern GMP facility in Schlattingen (TG) can produce up to 100 kg of active ingredients from Cannabis Sativa L. per day. This corresponds to the potential daily requirement of one to four million patients.

Contact

Canexis Pharma AG
Sebastian Zeller, CEO
+41 52 657 47 01
s.zeller@canexis.ch

About Canexis Pharma AG

Founded in 2020, Canexis Pharma AG develops pharmaceutical cannabis products to the highest scientific and regulatory standards. Its own GMP production facility in Schlattingen (Canton of Thurgau) has all the manufacturing and narcotics licenses required by the Swiss Agency for Therapeutic Products (Swissmedic). The company currently has around ten employees and supplies national and international partners with high-quality active ingredients and bulk finished drugs to improve patient care.